Company intelligence / Profile preview

LaserOptek

Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

LaserOptek's PALLAS laser is FDA-cleared and commercially available for treating pigmentation and inflammatory skin conditions. Clinical feedback from dermatologists indicates efficacy comparable to or superior to existing 308nm excimer lasers, with reduced operating costs and maintenance requirements due to solid-state technology eliminating need for gas and electrode replacements.

Therapeutic areas: Dermatology
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

Gale Force Aesthetics (exclusive U.S. distributor)Laser Service Solutions (U.S. service partner)

Beyond the preview

Go deeper on LaserOptek.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LaserOptek.

Explore the full profile